Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DLMAF

Go back to Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
INSMED (NASDAQ: INSM) Delayed: 97.85 +1.13 (1.17%)
Previous Close $96.72    52 Week High $19.30 
Open $95.12    52 Week Low $9.02 
Day High $98.51    P/E N/A 
Day Low $93.92    EPS $-1.69 
Volume 4,529,093